HIM
ENTA icon

Hillsdale Investment Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Hillsdale Investment Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.5M Buy
435,510
+13,210
+3% +$177K 0.15% 167
2025
Q4 		$6.66M Buy
+422,300
New +$5.36M 0.18% 141
2023
Q1 		– Sell
-53,300
Closed -$2.48M – 592
2022
Q4 		$2.48M Hold
53,300
– – 0.21% 150
2022
Q3 		$2.76M Hold
53,300
– – 0.25% 142
2022
Q2 		$2.52M Hold
53,300
– – 0.2% 153
2022
Q1 		$3.79M Sell
53,300
-650
-1% -$42.3K 0.25% 140
2021
Q4 		$4.04M Buy
+53,950
New +$4.23M 0.27% 127

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Hillsdale Investment Management's ENTA Position: Q1 2026 in Review

Hillsdale Investment Management increased its Enanta Pharmaceuticals (ENTA) stake by 3.1% in Q1 2026, buying an estimated $177K and bringing the position to 435,510 shares worth $5.5M. The position accounts for 0.15% of the portfolio, ranked #167.

Hillsdale Investment Management first reported a position in ENTA in Q4 2021 and has held it in 7 quarters since. The position peaked at $6.66M in Q4 2025. 133 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Hillsdale Investment Management held 435,510 shares of Enanta Pharmaceuticals worth $5.5M as of Q1 2026.
  • Hillsdale Investment Management bought 13,210 Enanta Pharmaceuticals shares in Q1 2026, an estimated $177K.
  • Enanta Pharmaceuticals made up 0.15% of Hillsdale Investment Management's portfolio in Q1 2026, its #167 holding.
  • Hillsdale Investment Management first reported a position in Enanta Pharmaceuticals in Q4 2021 and has held it in 7 quarters since.
  • Hillsdale Investment Management's Enanta Pharmaceuticals position peaked at $6.66M in Q4 2025.
  • 133 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Hillsdale Investment Management's 13F filing for Q1 2026, filed 4 May 2026.